SCHEMBL17525344

SCHEMBL17525344

Cc1ccc(S(=O)(=O)OCC2(C)CCC3(CC2)OCCO3)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
POLB P06746 2/20 0.41
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP3A4 P08684 2/20 0.39
CYP2C19 P33261 2/20 0.39
MAPK1 P28482 1/20 0.39
MMP2 P08253 2/20 0.39
ANPEP P15144 1/20 0.39
HSD17B10 Q99714 1/20 0.38
LMNA P02545 2/20 0.38
USP2 O75604 1/20 0.38
KDM4E B2RXH2 2/20 0.38
HTT P42858 1/20 0.37
CYP2C9 P11712 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16641783 0.88 KMT2A (0.49) ALDH1A1KMT2ASMN1; SMN2CYP3A4CYP2C19
SCHEMBL1701963 0.87 ALDH1A1 (0.41) ALDH1A1L3MBTL1POLBESR1ESR2
SCHEMBL10171744 0.84 CYP3A4 (0.48) ALDH1A1L3MBTL1KMT2ASMN1; SMN2CYP3A4
SCHEMBL15979026 0.84 MMP2 (0.40) ALDH1A1L3MBTL1POLBESR1ESR2
SCHEMBL16765322 0.83 ALDH1A1 (0.41) ALDH1A1L3MBTL1POLBESR1ESR2
SCHEMBL3598688 0.82 KMT2A (0.50) ALDH1A1POLBKMT2ASMN1; SMN2CYP3A4
SCHEMBL18213 0.82 KMT2A (0.54) ALDH1A1POLBKMT2ASMN1; SMN2CYP3A4
SCHEMBL29585185 0.82 ALDH1A1 (0.38) ALDH1A1L3MBTL1POLBESR1ESR2
SCHEMBL17005 0.81 KMT2A (0.42) ALDH1A1KMT2ASMN1; SMN2CYP3A4CYP2C19
SCHEMBL17902 0.81 KMT2A (0.53) ALDH1A1POLBKMT2ASMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4683912-A1 SUBSTITUTED THIOPHENE FUSED CYCLOHEXANONE DERIVATIVES, COMPOSITIONS COMPRISING THE SAME AND THEIR USE AS PHARMACEUTICALS Neurasic Therapeutics Inc. (CA) 2026-01-28 EP disclosed
WO-2025035205-A1 PHARMACEUTICAL COMBINATIONS COMPRISING A SUBSTITUTED THIOPHENE FUSED CYCLOHEXANONE DERIVATIVE AND A CYCLOOXYGENASE (COX) INHIBITOR, AND THEIR USE FOR THE TREATMENT OF PAIN NEURASIC THERAPEUTICS INC. (CA) 2025-02-20 WO disclosed
WO-2024192520-A1 SUBSTITUTED THIOPHENE FUSED CYCLOHEXANONE DERIVATIVES, COMPOSITIONS COMPRISING THE SAME AND THEIR USE AS PHARMACEUTICALS NEURASIC THERAPEUTICS INC. (CA) 2024-09-26 WO disclosed
US-9562033-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2017-02-07 US disclosed
US-20160039783-A1 Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses HIVIH (FR) 2016-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039783-A1 Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses POLRMT, MAVS, EIF2AK2 ALDH1A1 4105/4885L3MBTL1 1958/4885POLB 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.